Literature DB >> 33536561

B-cells expressing NgR1 and NgR3 are localized to EAE-induced inflammatory infiltrates and are stimulated by BAFF.

Maha M Bakhuraysah1,2, Paschalis Theotokis3, Jae Young Lee1,4, Amani A Alrehaili1,2, Pei-Mun Aui1, William A Figgett5, Michael F Azari1, John-Paul Abou-Afech1, Fabienne Mackay5,6, Christopher Siatskas7, Frank Alderuccio8, Stephen M Strittmatter9, Nikolaos Grigoriadis3, Steven Petratos10.   

Abstract

We have previously reported evidence that Nogo-A activation of Nogo-receptor 1 (NgR1) can drive axonal dystrophy during the neurological progression of experimental autoimmune encephalomyelitis (EAE). However, the B-cell activating factor (BAFF/BlyS) may also be an important ligand of NgR during neuroinflammation. In the current study we define that NgR1 and its homologs may contribute to immune cell signaling during EAE. Meningeal B-cells expressing NgR1 and NgR3 were identified within the lumbosacral spinal cords of ngr1+/+ EAE-induced mice at clinical score 1. Furthermore, increased secretion of immunoglobulins that bound to central nervous system myelin were shown to be generated from isolated NgR1- and NgR3-expressing B-cells of ngr1+/+ EAE-induced mice. In vitro BAFF stimulation of NgR1- and NgR3-expressing B cells, directed them into the cell cycle DNA synthesis phase. However, when we antagonized BAFF signaling by co-incubation with recombinant BAFF-R, NgR1-Fc, or NgR3 peptides, the B cells remained in the G0/G1 phase. The data suggest that B cells express NgR1 and NgR3 during EAE, being localized to infiltrates of the meninges and that their regulation is governed by BAFF signaling.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33536561      PMCID: PMC7858582          DOI: 10.1038/s41598-021-82346-6

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.996


  52 in total

1.  Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.

Authors:  Stephen L Hauser; Shibeshih Belachew; Ludwig Kappos
Journal:  N Engl J Med       Date:  2017-04-27       Impact factor: 91.245

2.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Authors:  Xavier Montalban; Stephen L Hauser; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Giancarlo Comi; Jérôme de Seze; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Fred Lublin; Kottil W Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Annette Sauter; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Hideki Garren; Nicole Mairon; Peter Chin; Jerry S Wolinsky
Journal:  N Engl J Med       Date:  2016-12-21       Impact factor: 91.245

3.  Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.

Authors:  Ludwig Kappos; Hans-Peter Hartung; Mark S Freedman; Alexey Boyko; Ernst Wilhelm Radü; Daniel D Mikol; Marc Lamarine; Yann Hyvert; Ulrich Freudensprung; Thomas Plitz; Johan van Beek
Journal:  Lancet Neurol       Date:  2014-03-06       Impact factor: 44.182

4.  BAG3 p.Pro209Ser mutation identified in a Chinese family with Charcot-Marie-Tooth disease.

Authors:  Jun Fu; Mingming Ma; Jia Song; Mi Pang; Gang Li; Jiewen Zhang
Journal:  J Neurol       Date:  2019-12-18       Impact factor: 4.849

5.  Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.

Authors:  Ludwig Kappos; David Li; Peter A Calabresi; Paul O'Connor; Amit Bar-Or; Frederik Barkhof; Ming Yin; David Leppert; Robert Glanzman; Jeroen Tinbergen; Stephen L Hauser
Journal:  Lancet       Date:  2011-10-31       Impact factor: 79.321

Review 6.  Immunopathology of multiple sclerosis.

Authors:  Calliope A Dendrou; Lars Fugger; Manuel A Friese
Journal:  Nat Rev Immunol       Date:  2015-08-07       Impact factor: 53.106

7.  Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis.

Authors:  Arumugam Palanichamy; Leonard Apeltsin; Tracy C Kuo; Marina Sirota; Shengzhi Wang; Steven J Pitts; Purnima D Sundar; Dilduz Telman; Lora Z Zhao; Mia Derstine; Aya Abounasr; Stephen L Hauser; H-Christian von Büdingen
Journal:  Sci Transl Med       Date:  2014-08-06       Impact factor: 17.956

8.  B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes.

Authors:  Joel N H Stern; Gur Yaari; Jason A Vander Heiden; George Church; William F Donahue; Rogier Q Hintzen; Anita J Huttner; Jon D Laman; Rashed M Nagra; Alyssa Nylander; David Pitt; Sriram Ramanan; Bilal A Siddiqui; Francois Vigneault; Steven H Kleinstein; David A Hafler; Kevin C O'Connor
Journal:  Sci Transl Med       Date:  2014-08-06       Impact factor: 17.956

9.  BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma.

Authors:  Markus Krumbholz; Diethilde Theil; Tobias Derfuss; Andreas Rosenwald; Frank Schrader; Camelia-Maria Monoranu; Susan L Kalled; Donna M Hess; Barbara Serafini; Francesca Aloisi; Hartmut Wekerle; Reinhard Hohlfeld; Edgar Meinl
Journal:  J Exp Med       Date:  2005-01-10       Impact factor: 14.307

10.  The relation between inflammation and neurodegeneration in multiple sclerosis brains.

Authors:  Josa M Frischer; Stephan Bramow; Assunta Dal-Bianco; Claudia F Lucchinetti; Helmut Rauschka; Manfred Schmidbauer; Henning Laursen; Per Soelberg Sorensen; Hans Lassmann
Journal:  Brain       Date:  2009-03-31       Impact factor: 13.501

View more
  4 in total

1.  Distinct binding mode of BAFF antagonist antibodies belimumab and tabalumab, analyzed by computer simulation.

Authors:  Yaxin Jiang; Jian Sun; Jing Wei
Journal:  J Mol Model       Date:  2022-09-05       Impact factor: 2.172

Review 2.  Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases.

Authors:  Panos Stathopoulos; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2022-02-18       Impact factor: 6.088

Review 3.  Novel contributors to B cell activation during inflammatory CNS demyelination; An oNGOing process.

Authors:  Olympia Damianidou; Paschalis Theotokis; Nikolaos Grigoriadis; Steven Petratos
Journal:  Int J Med Sci       Date:  2022-01-01       Impact factor: 3.738

Review 4.  Microbiota, IgA and Multiple Sclerosis.

Authors:  Léo Boussamet; Muhammad Shahid Riaz Rajoka; Laureline Berthelot
Journal:  Microorganisms       Date:  2022-03-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.